The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Finasteride is known to improve urinary symptoms in men with benign prostatic hyperplasia, but the extent to which the benefit is sustained and whether finasteride reduces the incidence of related events, including the need for surgery and the development of acute urinary retention, is not known. METHODS: In this double-blind, randomized, placebo-controlled trial, we studied 3040 men with moderate-to-severe urinary symptoms and enlarged prostate glands who were treated daily with 5 mg of finasteride or placebo for four years. Symptom scores (on a scale of 1 to 34), urinary flow rates, and the occurrence of outcome events were assessed every four months in 3016 men. Prostate volume was measured in a subgroup of the men. Complete data on outcomes were available for 2760 men. RESULTS: During the four-year study period, 152 of the 1503 men in the placebo group (10 percent) and 69 of the 1513 men in the finasteride group (5 percent) underwent surgery for benign prostatic hyperplasia (reduction in risk with finasteride, 55 percent; 95 percent confidence interval, 41 to 65 percent). Acute urinary retention developed in 99 men (7 percent) in the placebo group and 42 men (3 percent) in the finasteride group (reduction in risk with finasteride, 57 percent; 95 percent confidence interval, 40 to 69 percent). Among the men who completed the study, the mean decreases in the symptom score were 3.3 in the finasteride group and 1.3 in the placebo group (P<0.001). Treatment with finasteride also significantly improved urinary flow rates and reduced prostate volume (P<0.001). CONCLUSIONS: Among men with symptoms of urinary obstruction and prostatic enlargement, treatment with finasteride for four years reduces symptoms and prostate volume, increases the urinary flow rate, and reduces the risk of surgery and acute urinary retention.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inhibitors of the type 2 enzyme have been developed for the treatment of prostatic hyperplasia and the prevention of its recurrence after surgery (554): finasteride selectively inhibits human 5␣-reductase type 2, whereas dutasteride inhibits both isoenzymes.”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [554]
In the citing paper
“The proof-of-concept has been established by aromatase inhibition in breast cancer and 5α-reductase inhibition in prostate hyperplasia (Chumsri et al., 2011, Lowe et al., 2003, McConnell et al., 1998).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as McConnell et al., 1998
Citations
Cites
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & The Measurement Committee of the American Urological Association (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36966-5 · Cited by 3,436
Self-citationThe Effect of Finasteride in Men with Benign Prostatic Hyperplasia
Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210223271701 · Cited by 1,124
Self-citationThe Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia
Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., & Padley, R. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350801 · Cited by 792
Natural History of Prostatism: Risk Factors for Acute Urinary Retention
Jacobsen, S. J., Jacobson, D. J., Girman, C. J., Roberts, R. O., Rhodes, T., Guess, H. A., & Lieber, M. M. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64508-7 · Cited by 672
Self-citationWasson, J. H., Reda, D. J., Bruskewitz, R. C., Elinson, J., Keller, A. M., & Henderson, W. G. (1995) · New England Journal of Medicine · doi:10.1056/nejm199501123320202 · Cited by 605
Self-citationBoyle, P., Lawrence Gould, A., & Roehrborn, C. G. (1996) · Urology · doi:10.1016/s0090-4295(96)00353-6 · Cited by 469
Self-citationMcConnell, J. D. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.74.3.505 · Cited by 325
Self-citationAlfuzosin for treatment of benign prostatic hypertrophy
Jardin, A., Bensadoun, H., Delauche-Cavallier, M. C., Attatli, P., & The BPH-ALF Group (1991) · The Lancet · doi:10.1016/0140-6736(91)93140-5 · Cited by 241
Nickel, J. C., Fradet, Y., Boake, R., Pommerville, P. J., Perreault, J., Afridi, S. K., & ELHILALI, M. M. (1996) · Europe PMC (PubMed Central) · Cited by 225
Self-citationBenign Prostatic Hyperplasia — Medical and Minimally Invasive Treatment Options
Oesterling, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199501123320207 · Cited by 211
Roehrborn, C. G., Oesterling, J. E., Auerbach, S., Kaplan, S. A., Keith Lloyd, L., Milam, D. F., & Padley, R. J. (1996) · Urology · doi:10.1016/s0090-4295(99)80409-9 · Cited by 207
Self-citationBarry, M. J., Fowler, F. J. J., Bin, L., Pitts, J. C., Harris, C. J., & Mulley, A. G. J. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65267-4 · Cited by 193
Finasteride (MK‐906) in the treatment of benign prostatic hyperplasia
The Finasteride Study Group (1993) · The Prostate · doi:10.1002/pros.2990220403 · Cited by 171
Benign Prostatic Hyperplasia: Antecedents and Natural History
Guess, H. A. (1992) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036083 · Cited by 167
Roehrborn, C. G., Girman, C. J., Rhodes, T., Hanson, K. A., Collins, G. N., Sech, S. M., Jacobsen, S. J., Garraway, W. M., & Lieber, M. M. (1997) · Urology · doi:10.1016/s0090-4295(97)00031-9 · Cited by 166
Self-citationAndersen, J. T., Curtis Nickel, J., Marshall, V. R., Schulman, C. C., & Boyle, P. (1997) · Urology · doi:10.1016/s0090-4295(97)00185-4 · Cited by 161
Self-citationAndersen, J. T., Ekman, P., Wolf, H., Beisland, H. O., Johansson, J. E., Kontturi, M., Lehtonen, T., & Tveter, K. (1995) · Urology · doi:10.1016/s0090-4295(99)80291-x · Cited by 160
Benign prostatic hyperplasia: A review of its histogenesis and natural history
Oesterling, J. E. (1996) · The Prostate · doi:10.1002/(sici)1097-0045(1996)6+<67::aid-pros13>3.0.co;2-p · Cited by 141
Girman, C. J., Epstein, R. S., Jacobsen, S. J., Guess, H. A., Panser, L. A., Oesterling, J. E., & Lieber, M. M. (1994) · Urology · doi:10.1016/s0090-4295(94)80165-7 · Cited by 135
Self-citationProstatectomy: Patients' Perception and Long‐term Follow‐UP
Malone, P. R., COOK, A., EDMONSON, R. S., GILL, M. W., & SHEARER, R. J. (1988) · British Journal of Urology · doi:10.1111/j.1464-410x.1988.tb06386.x · Cited by 91
Size and Power of Two-Sample Tests of Repeated Measures Data
Dawson, J. D., & Lagakos, S. W. (1993) · Biometrics · doi:10.2307/2532244 · Cited by 82
Byrnes, C. A., Morton, A. S., Liss, C. L., Lippert, M. C., & Gillenwater, J. Y. (1995) · Clinical Therapeutics · doi:10.1016/0149-2918(95)80073-5 · Cited by 72
Validation of a symptoms questionnaire for benign prostatic hyperplasia
Bolognese, J. A., Grino, P. B., Stoner, E., Kozloff, R. C., Kunitz, S. C., & Patrick, D. L. (1992) · The Prostate · doi:10.1002/pros.2990210308 · Cited by 59
The Identification of Patients at Risk from Acute Retention
POWELL, P. H., SMITH, P. J. B., & Feneley, R. C. L. (1980) · British Journal of Urology · doi:10.1111/j.1464-410x.1980.tb03104.x · Cited by 55
Genetic regulation of androgen action
Kallio, P. J., Palvimo, J. J., & Jänne, O. A. (1996) · The Prostate · doi:10.1002/(sici)1097-0045(1996)6+<52::aid-pros10>3.0.co;2-q · Cited by 19
Management of Acute Retention of Urine: A Reappraisal
Higgins, P. M., French, M., & CHADALAVADA, V. S. R. (1991) · British Journal of Urology · doi:10.1111/j.1464-410x.1991.tb15163.x · Cited by 12
Research works printed but not linked: 4
- McConnell JD, 1994, Clin Pract Guidel, 8, 7
- Nickel JC, 1996, Can Med Assoc J, 155, 1251
- McConnell JD, Roehrborn CG. Patient selection and symptom evaluation. In: Chisholm GD, ed. Handbook on benign prostatic hyperplasia. New York: Raven Press, 1994:33-51.
- Somers WJ, 1996, J Urol, 155, 586A
Cited by
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Self-citationThe Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., Lepor, H., McVary, K. T., Nyberg, L. M., Clarke, H. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030656 · Cited by 2,043
Self-citationOelke, M., Bachmann, A., Descazeaud, A., Emberton, M., Gravas, S., Michel, M. C., N'Dow, J. M., Nordling, J., & de la Rosette, J. J. M. C. H. (2013) · European Urology · doi:10.1016/j.eururo.2013.03.004 · Cited by 1,344
UROLOGIC DISEASES IN AMERICA PROJECT: BENIGN PROSTATIC HYPERPLASIA
Wei, J. T., Calhoun, E. A., & Jacobsen, S. J. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000155709.37840.fe · Cited by 851
Metadata
- Authors
- McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., Taylor, A. M., & Waldstreicher, J.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- University of Wisconsin System (US)
- Johns Hopkins University (US)
- Washington University in St. Louis (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- UConn Health (US)
- Queen's University (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-02-26
- Volume
- 338
- Issue
- 9
- Pages
- 557-563
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2804551733
- Cited by
- 1,120
- References
- 25
- Citations by year
- 2026: 12 · 2025: 10 · 2024: 15 · 2023: 18 · 2022: 18 · 2021: 29 · 2020: 22 · 2019: 25 · 2018: 29 · 2017: 27 · 2016: 31 · 2015: 31 · 2014: 42 · 2013: 39 · 2012: 54
- FWCI
- 68.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Urology › Urinary Tract Infections Management
- Keywords
- finasteride, benign prostatic hyperplasia, acute urinary retention, surgical treatment, prostate volume, urinary flow rate, lower urinary tract symptoms, urinary tract obstruction, 5-alpha reductase inhibitors
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Humans, Male, Middle Aged, Prostate, Prostatic Hyperplasia, Urination, Incidence, Urinary Retention, Finasteride, 5-alpha Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.